Payment overview · 2025
General Payments
$186.88
9 reported records · 5 companies
Healthcare provider profile · identity verified
Alberto R Gutierrez, DO
Allopathic & Osteopathic Physicians|Family Medicine|Sports Medicine · LAND O LAKES, FL · NPI 1386014652
Verified facts
What the public records show
CMS Open Payments records show Alberto R Gutierrez, DO received $186.88 in general payments during 2025 across 9 reported records.
Lilly USA, LLC accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.23 | 52.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.56 | 18.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.68 | 13.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.86 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.55 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.88 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.37 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.16 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 825 | 246 |
| Losartan Potassium | Losartan Potassium | 562 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 157 |
| Lisinopril | Lisinopril | 453 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 100 |
| Metformin Hcl | Metformin Hcl | 302 | 87 |
| Omeprazole | Omeprazole | 289 | 90 |
| Simvastatin | Simvastatin | 280 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 79 |
| Methylprednisolone | Methylprednisolone | 246 | 179 |
| Gabapentin | Gabapentin | 245 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 66 |
| Trazodone Hcl | Trazodone Hcl | 164 | 50 |
| Montelukast Sodium | Montelukast Sodium | 148 | 44 |
| Allopurinol | Allopurinol | 139 | 41 |
| Furosemide | Furosemide | 134 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 40 |
| Alprazolam | Alprazolam | 128 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 118 | 98 |
| Carvedilol | Carvedilol | 114 | 36 |
| Sertraline Hcl | Sertraline Hcl | 114 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 44 |
| Azithromycin | Azithromycin | 97 | 77 |
| Famotidine | Famotidine | 95 | 30 |
| Glimepiride | Glimepiride | 92 | 30 |
| Meloxicam | Meloxicam | 92 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 31 |
| Potassium Chloride | Potassium Chloride | 91 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 37 |
| Ezetimibe | Ezetimibe | 75 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 33 |
| Atenolol | Atenolol | 69 | 19 |
| Eliquis | Apixaban | 69 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 36 |
| Donepezil Hcl | Donepezil Hcl | 63 | 17 |
| Alendronate Sodium | Alendronate Sodium | 61 | 17 |
| Temazepam | Temazepam | 58 | 12 |
| Finasteride | Finasteride | 57 | 19 |
| Lovastatin | Lovastatin | 57 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Methocarbamol | Methocarbamol | 52 | 28 |
| Warfarin Sodium | Warfarin Sodium | 51 | 15 |
| Irbesartan | Irbesartan | 49 | 14 |
| Glipizide | Glipizide | 48 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 13 |
| Baclofen | Baclofen | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Clonazepam | Clonazepam | 47 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 41 |
| Fenofibrate | Fenofibrate | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Valacyclovir | Valacyclovir Hcl | 45 | 26 |
| Ibuprofen | Ibuprofen | 36 | 17 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Jantoven | Warfarin Sodium | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 11 |
| Amoxicillin | Amoxicillin | 33 | 21 |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Novolog | Insulin Aspart | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Spironolactone | Spironolactone | 33 | 14 |
| Valsartan | Valsartan | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 12 |
| Nystatin | Nystatin | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 25 |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 12 |
| Ibu | Ibuprofen | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | 13 |
| Bumetanide | Bumetanide | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.88 · 9 records | Lilly USA, LLC | Cologuard Collection Kit, Dexcom G6 Transmitter, KISUNLA, MOUNJARO, SHINGRIX, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error